Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford to lead work towards more personalised care for patients

General Innovation Research

Oxford is today named as a centre for excellence leading the drive to tailor more treatments to the needs of individual patients.

A Precision Medicine Catapult centre will be established in Oxford bringing together business and research to develop new products and services.

This project will be led by the Oxford Academic Health Science Network which will connect partners across the NHS, universities, research and industry with a particular focus on harnessing big data and developing new diagnostic tests. The aim is to accelerate the adoption of innovation in the NHS at pace and scale.

The announcement that Oxford will be one of six regional centres of excellence came from the Precision Medicine Catapult, funded by Innovate UK.

Read more (Oxford Academic Health Science Network website)

Similar stories

Oxford University wins prestigious Queen’s Anniversary Prize

Her Majesty The Queen has approved the award of The Queen’s Anniversary Prizes to twenty-one higher and further education institutions, including Oxford University, in the most recent round of the independently reviewed scheme. This prestigious award is the highest national honour available to universities and FE colleges across the UK.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

How moving dots are helping us learn more about dyslexia in children – new research

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.